BRPI0406800A - Peptìdio dimerizado - Google Patents
Peptìdio dimerizadoInfo
- Publication number
- BRPI0406800A BRPI0406800A BR0406800-9A BRPI0406800A BRPI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- tumor antigen
- dimerized peptide
- antigen peptide
- dimerized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-007122 | 2003-01-15 | ||
JP2003007122 | 2003-01-15 | ||
PCT/JP2004/000254 WO2004063217A1 (ja) | 2003-01-15 | 2004-01-15 | 二量体化ペプチド |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0406800A true BRPI0406800A (pt) | 2006-01-17 |
BRPI0406800A8 BRPI0406800A8 (pt) | 2016-11-01 |
BRPI0406800B1 BRPI0406800B1 (pt) | 2020-08-11 |
BRPI0406800B8 BRPI0406800B8 (pt) | 2021-05-25 |
Family
ID=32709100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0406800A BRPI0406800B8 (pt) | 2003-01-15 | 2004-01-15 | "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060217297A1 (pt) |
EP (2) | EP2154145B1 (pt) |
JP (2) | JP4498274B2 (pt) |
KR (2) | KR20120054644A (pt) |
CN (2) | CN1756763B (pt) |
AT (1) | ATE444969T1 (pt) |
AU (1) | AU2004204031B2 (pt) |
BR (1) | BRPI0406800B8 (pt) |
CA (1) | CA2513701C (pt) |
DE (1) | DE602004023476D1 (pt) |
ES (1) | ES2332590T3 (pt) |
HK (2) | HK1081975A1 (pt) |
WO (1) | WO2004063217A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1560078B (zh) * | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
CA2440303C (en) * | 2001-03-22 | 2013-03-19 | Haruo Sugiyama | Wt1 modified peptide |
WO2002097044A2 (en) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
ES2538486T3 (es) * | 2002-09-12 | 2015-06-22 | International Institute Of Cancer Immunology, Inc. | Preparación de péptidos antigénicos contra el cáncer |
KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
SI1731605T1 (sl) * | 2004-03-31 | 2010-07-30 | Internat Inst Of Cancer Immunolog Inc | Peptidi antigena karcinoma izvedeni iz WT1 |
RU2396088C2 (ru) * | 2005-02-04 | 2010-08-10 | СУРВАК АпС | Вакцина на основе пептидов сурвивина |
CN101336249A (zh) | 2005-11-30 | 2008-12-31 | 株式会社癌免疫研究所 | 新型肽化合物 |
PL1988163T3 (pl) | 2006-02-22 | 2012-11-30 | Int Inst Cancer Immunology Inc | Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna |
ATE443722T1 (de) * | 2006-02-23 | 2009-10-15 | Fibrex Medical Res & Dev Gmbh | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung |
CA2886619A1 (en) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
CN104774910B (zh) | 2007-02-27 | 2018-04-10 | 株式会社癌免疫研究所 | 活化辅助t细胞的方法以及用于该方法的组合物 |
AU2008292913B2 (en) * | 2007-08-30 | 2014-06-05 | Curedm Group Holdings, Llc | Compositions and methods of using proislet peptides and analogs thereof |
ES2849187T3 (es) | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
NZ611176A (en) | 2010-12-02 | 2015-07-31 | Bionor Immuno As | Peptide scaffold design |
JP5893640B2 (ja) * | 2010-12-23 | 2016-03-23 | ファルネファ オーストリア ゲーエムベーハー | Oprf/i試薬と入院および他の患者におけるその利用 |
MX346475B (es) | 2011-01-06 | 2017-03-22 | Bionor Immuno As | Peptidos inmunogenicos monomericos y multimericos. |
WO2012105224A1 (ja) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | ワクチン・アジュバント |
ES2655031T3 (es) | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
JP6530192B2 (ja) | 2012-12-17 | 2019-06-12 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
DK2982681T3 (en) * | 2013-03-29 | 2018-12-10 | Sumitomo Dainippon Pharma Co Ltd | WT1 ANTIGENPEPTIDKONJUGATVACCINE |
JP6671956B2 (ja) * | 2013-03-29 | 2020-03-25 | 大日本住友製薬株式会社 | Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン |
EP3059242A4 (en) | 2013-10-17 | 2017-04-19 | Seoul National University R&DB Foundation | Alpha helix cell-penetrating peptide multimer, preparation method therefor and use thereof |
US10471136B2 (en) | 2014-09-27 | 2019-11-12 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition for injection |
JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
CN107921106B (zh) * | 2015-05-20 | 2023-09-08 | 住友制药株式会社 | Wt1抗原肽和免疫调节剂的组合用途 |
EP3322989A1 (en) | 2015-07-14 | 2018-05-23 | Yeda Research and Development Co., Ltd. | Peptide combinations for use in the diagnosis of schizophrenia |
US20200368338A1 (en) * | 2017-12-27 | 2020-11-26 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate of wt1-derived peptides and composition comprising the same |
US20240207426A1 (en) * | 2022-12-22 | 2024-06-27 | Defence Therapeutics Inc. | Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0841068B1 (en) * | 1995-06-01 | 2006-07-12 | Kishimoto, Tadamitsu | Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1) |
JP3060287B2 (ja) | 1995-10-09 | 2000-07-10 | 参天製薬株式会社 | アパファントを主薬とする水性点眼剤 |
CN1560078B (zh) * | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
CA2349442C (en) * | 1998-09-30 | 2012-12-04 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
WO2002047474A1 (fr) | 2000-12-13 | 2002-06-20 | Sumitomo Pharmaceuticals Company, Limited | Animaux transgeniques exprimant hla-a24 et utilisation de ceux-ci |
CA2440303C (en) * | 2001-03-22 | 2013-03-19 | Haruo Sugiyama | Wt1 modified peptide |
US8735357B2 (en) * | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
JPWO2003028758A1 (ja) * | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的t細胞の誘導方法 |
ATE466084T1 (de) * | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
SI1731605T1 (sl) | 2004-03-31 | 2010-07-30 | Internat Inst Of Cancer Immunolog Inc | Peptidi antigena karcinoma izvedeni iz WT1 |
-
2004
- 2004-01-15 US US10/541,821 patent/US20060217297A1/en not_active Abandoned
- 2004-01-15 CA CA2513701A patent/CA2513701C/en not_active Expired - Lifetime
- 2004-01-15 KR KR1020127008760A patent/KR20120054644A/ko not_active Application Discontinuation
- 2004-01-15 EP EP09172205.8A patent/EP2154145B1/en not_active Expired - Lifetime
- 2004-01-15 AT AT04702444T patent/ATE444969T1/de not_active IP Right Cessation
- 2004-01-15 EP EP04702444A patent/EP1584627B1/en not_active Expired - Lifetime
- 2004-01-15 ES ES04702444T patent/ES2332590T3/es not_active Expired - Lifetime
- 2004-01-15 DE DE602004023476T patent/DE602004023476D1/de not_active Expired - Lifetime
- 2004-01-15 CN CN2004800058473A patent/CN1756763B/zh not_active Expired - Lifetime
- 2004-01-15 KR KR1020057012761A patent/KR101399678B1/ko active IP Right Grant
- 2004-01-15 CN CN201010156098A patent/CN101851275A/zh active Pending
- 2004-01-15 JP JP2005508011A patent/JP4498274B2/ja not_active Expired - Lifetime
- 2004-01-15 BR BRPI0406800A patent/BRPI0406800B8/pt active IP Right Grant
- 2004-01-15 WO PCT/JP2004/000254 patent/WO2004063217A1/ja active Application Filing
- 2004-01-15 AU AU2004204031A patent/AU2004204031B2/en not_active Expired
-
2006
- 2006-02-23 HK HK06102442.4A patent/HK1081975A1/xx not_active IP Right Cessation
-
2009
- 2009-11-16 JP JP2009260957A patent/JP4926231B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-07 US US12/795,187 patent/US8242084B2/en not_active Expired - Lifetime
- 2010-08-16 HK HK10107803.0A patent/HK1141539A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20060217297A1 (en) | 2006-09-28 |
JP4926231B2 (ja) | 2012-05-09 |
EP1584627A4 (en) | 2006-03-15 |
CN101851275A (zh) | 2010-10-06 |
AU2004204031B2 (en) | 2010-03-04 |
KR20120054644A (ko) | 2012-05-30 |
JPWO2004063217A1 (ja) | 2006-06-01 |
KR101399678B1 (ko) | 2014-05-27 |
HK1141539A1 (en) | 2010-11-12 |
BRPI0406800B8 (pt) | 2021-05-25 |
ES2332590T3 (es) | 2010-02-09 |
CN1756763B (zh) | 2010-05-26 |
US20100292164A1 (en) | 2010-11-18 |
JP2010047603A (ja) | 2010-03-04 |
HK1081975A1 (en) | 2006-05-26 |
DE602004023476D1 (de) | 2009-11-19 |
WO2004063217A1 (ja) | 2004-07-29 |
EP2154145A3 (en) | 2010-05-19 |
CA2513701C (en) | 2013-06-18 |
EP2154145A2 (en) | 2010-02-17 |
CN1756763A (zh) | 2006-04-05 |
BRPI0406800A8 (pt) | 2016-11-01 |
US8242084B2 (en) | 2012-08-14 |
AU2004204031A1 (en) | 2004-07-29 |
KR20050098863A (ko) | 2005-10-12 |
ATE444969T1 (de) | 2009-10-15 |
CA2513701A1 (en) | 2004-07-29 |
EP1584627A1 (en) | 2005-10-12 |
BRPI0406800B1 (pt) | 2020-08-11 |
EP2154145B1 (en) | 2013-04-24 |
EP1584627B1 (en) | 2009-10-07 |
JP4498274B2 (ja) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0406800A8 (pt) | Peptídio dimerizado | |
CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
WO2003102157A3 (en) | Synthetic antibody phage libraries | |
WO2007064919A3 (en) | Binding polypeptides with restricted diversity sequences | |
CY1117031T1 (el) | Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου | |
DK1625209T3 (da) | Kimære immunoglobulin-monomer-dimer-hybrider | |
CY1113850T1 (el) | Νεα παραγωγα ινσουλινης | |
DK1718677T3 (da) | Monovalente antistoffragmenter egnede som terapeutiske midler | |
ATE545703T1 (de) | Multivalentes zielbindendes protein | |
ATE497975T1 (de) | Il-21-varianten | |
CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
DE60238993D1 (de) | Hybrid und tandemproteine von neisseria sp | |
DE602005008996D1 (de) | Radiofluorierte peptide | |
RS54046B1 (en) | ANTI-MIOSTATIN ANTITELA | |
WO2005012531A3 (en) | Antibody cdr polypeptide sequences with restricted diversity | |
WO2005003171A3 (en) | Modified antibody fragments | |
DK1454138T3 (da) | Immunocytokiner med moduleret selektivitet | |
ATE415413T1 (de) | Iap-bindende verbindungen | |
HK1071898A1 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
IL172729A0 (en) | Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins | |
ATE543833T1 (de) | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen | |
DE502004011395D1 (de) | Protein-bindende doxorubicin-peptid-derivate | |
PE20050962A1 (es) | Anticuerpos completamente humanos contra 4-1bb humano | |
EP2305710A3 (en) | Synthetic antibody phage libraries | |
ATE467421T1 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA (CHUGAI PHARMACEUT |
|
B25A | Requested transfer of rights approved |
Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25D | Requested change of name of applicant approved |
Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP) |
|
B25G | Requested change of headquarter approved |
Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP) |